Zimmer Biomet Holdings Announces Pricing of Secondary Offering
WARSAW — Zimmer Biomet Holdings Inc. announced the pricing of the previously announced underwritten secondary offering of 11,027,558 shares of its common stock by certain of its stockholders, consisting of affiliates of Blackstone and Goldman Sachs.
The shares are being sold to the public at an initial price of $96.45 per share. The selling stockholders will receive all of the proceeds of the offering. Neither Zimmer Biomet nor any of its directors, officers or other stockholders is selling any shares of common stock in the offering. The closing of the offering is expected to occur Feb. 10, subject to the satisfaction of customary closing conditions.
Subject to the closing of the offering, Zimmer Biomet will purchase from the underwriter $250 million of the shares of common stock being sold by the selling stockholders at a price per share equal to the weighted average per share purchase price payable by the underwriter to the selling stockholders.
Barclays Capital Inc. is acting as the sole underwriter for the offering.
Zimmer Biomet has filed a registration statement, including a base prospectus, with the U.S. Securities and Exchange Commission relating to these securities. The offering of these securities was made only by means of a written prospectus forming part of the effective registration statement.
The base prospectus and the preliminary prospectus supplement have been filed with the SEC and are available on the SEC’s website. A copy of the final prospectus supplement related to the offering will be filed with the SEC and may be obtained, when available, from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Ave., Edgewood, NY 11717, via email at [email protected] or at (888) 603-5847.